NCT01610869已完成2 期
Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 117
- 试验地点
- 16
- 主要终点
- Overall survival
研究概览
简要总结
The primary objective is to explore the efficacy and safety of an all oral combination of BIBF 1120 (an inhibitor of angiogenic signalling) and metronomic cyclophosphamide in patients with multiply-relapsed advanced ovarian cancer, who have completed a minimum of two lines of previous chemotherapy and who for any reason are not suitable for further 'standard' intravenous chemotherapy treatments.
详细描述
A randomised placebo controlled double blind multi-centre phase II trial: BIBF 1120 200mg bd plus 100mg daily of oral cyclophosphamide (experimental arm) or oral cyclophosphamide 100mg daily plus placebo (control arm). Patients will receive oral BIBF 1120 and cyclophosphamide or cyclophosphamide and placebo continuously until disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female subjects, ≥18 years, histologically proven recurrent advanced epithelial ovarian, fallopian tube or primary peritoneal carcinomas
- •Have either undergone a hysterectomy or bilateral oophorectomy/salpingectomy and/or have been postmenopausal for 24 consecutive months (i.e. who have not had menses at any time in the preceding 24 consecutive months without an alternative medical cause)
- •Performance status 0-2
- •Adequate organ function
- •Life expectancy >6 weeks
- •Has received 2 or more lines of chemotherapy for ovarian cancer and patient is platinum resistant or platinum intolerant or not suitable for any further standard intravenous chemotherapy
- •No previous oral cyclophosphamide, nintedanib, or other tyrosine kinase inhibitors such as cediranib but patients can have received anti-VEGF therapies such as bevacizumab as they will be stratified for this
- •Measurable lesions according to RECIST 1.1 criteria or serum CA125 levels for evaluation by GCIG CA125 criteria are welcomed but not a prerequisite for inclusion as response will only be assessed for those with evaluable disease
- •Able to give written informed consent and to complete QoL
- •Exclusion Criteria
- •Carcinosarcoma or malignant tumour of non-epithelial origin (e.g. germ cell tumour, sex cord-stromal tumour) of the ovary, fallopian tube or peritoneum
- •Clinically relevant non-healing wound, ulcer (intestinal tract, skin) or bone fracture
- •Symptoms or signs of gastrointestinal obstruction requiring parenteral nutrition or hydration or any other GI disorders or abnormalities that would interfere with drug absorption or inability to take oral medication
- •Active brain metastases (i.e. symptoms deteriorating, changing condition in < 4 weeks) or leptomeningeal disease. Trial entry is allowed if the brain metastases are stable (asymptomatic or condition stable for > 4 weeks).
- •Dexamethasone for brain metastases is allowed if administered as stable dose for > 4 weeks before randomisation (if < 4 weeks then the patient is not eligible)
- •Clinically relevant therapy-related toxicity from previous chemotherapy and radiotherapy
- •History of major thromboembolic event within the last 6 months, such as pulmonary embolism or proximal deep vein thrombosis, unless on stable therapeutic anticoagulation (>3 months if on warfarin, PT / INR needs to be monitored regularly as per table 8.1 in protocol)
- •Known inherited or acquired bleeding disorder
- •Significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within the past 6 months, congestive heart failure > NYHA II, severe peripheral vascular disease, significantly relevant pericardial effusion
- •History of a cerebral vascular accident, transient ischemic attack or subarachnoid hemorrhage within the past 6 months
- •Radiographic evidence of cavitating or necrotic tumours with invasion of adjacent major blood vessels
- •Laboratory values indicating an increased risk for adverse events:
- •calculated GFR < 45 ml/min. Sites can use any calculation method according to local practice.
- •absolute neutrophil count (ANC) < 1.5x109/L
- •platelets < 100 x109/L
- •haemoglobin < 90 g/L
- •proteinuria CTCAE 2 or greater
- •total bilirubin > x 2 ULN
- •ALT and/or AST > 1.5 x ULN
- •unless liver metastases present when ALT or AST > 2.5 ULN
- •International normalized ratio (INR) > 2 or activated partial thromboplastin time (APTT) >1.5 x ULN in the absence of therapeutic anticoagulation. INR > 4 or APTT > 2.5 x ULN in presence of therapeutic anticoagulation
- •Serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal or antiviral therapy), including hepatitis B and/or C infection, HIV- infection
- •Poorly controlled diabetes mellitus or patient on sulphonylurea-type hypoglycaemics (e.g. gliclazide) as main diabetic control (as contraindicated with cyclophosphamide)
- •Previous breast cancer patients are permitted only if diagnosis and any chemotherapy treatment for this was > 5 years previously and there is no evidence of metastatic breast cancer at trial entry (Please contact UCL CTC / CI if patient still on hormone treatment for breast cancer).
- •Other malignancy diagnosed within the past 5 years. In exception to this rule, the following malignancies may be included:
- •non-melanoma skin cancer (if adequately treated)
- •cervical carcinoma in situ (if adequately treated)
- •prior or synchronous endometrial cancer (if adequately treated), provided all of the following criteria are met: G1 or G2, no LVSI and FIGO (2010) stage IA only
- •Serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease or a laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study
- •Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule e.g. active alcohol or drug abuse
- •Any contraindications for therapy with cyclophosphamide, e.g. a history of severe hypersensitivity reactions to listed excipients for cyclophosphamide treatment with other investigational drugs
- •Patients should not commence trial treatment within 6 weeks of any major surgical procedure
- •Participation in another clinical trial testing a drug within the past four weeks before start of therapy or concomitantly with this trial
- •Chemotherapy, including immunotherapy or monoclonal antibody treatment (VEGF) within 4 weeks of starting study treatment
- •Hormone treatment for ovarian cancer within 2 weeks of starting study treatment (ongoing HRT is allowable)
- •Any previous tyrosine kinase inhibitor treatment that has predominantly anti-angiogenic action
- •Radiotherapy within 3 months not allowed except when given for symptom control >28d previously. All patients receiving any radiotherapy will require evidence of recurrent ovarian cancer outside the irradiated field either on imaging or via rising CA125
- •Hypersensitivity to nintedanib, peanut or soya, or to any of the excipients of nintedanib
排除标准
- 未提供
研究组 & 干预措施
Cyclophosphamide and BIBF-1120
Experimental
Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
干预措施: BIBF 1120 (Drug)
Cyclophosphamide and placebo
Placebo Comparator
Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
干预措施: BIBF 1120 (Drug)
结局指标
主要结局
Overall survival
时间窗: After follow-up is complete (year 3-4 of the trial)
To be measured in days, from the date of randomisation to the date of death.
次要结局
- Quality of life and qualitative health data(After follow-up is complete (year 3-4 of the trial))
- Adverse events for all patients(After follow-up is complete (year 3-4 of the trial))
- Progression free survival(After follow-up is complete (year 3-4 of the trial))
研究者
研究点 (16)
Loading locations...
相似试验
已完成
3 期
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00805194Boehringer Ingelheim1,314
已完成
2 期
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate CancerProstatic NeoplasmsNCT02182063Boehringer Ingelheim81
已完成
3 期
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLCCarcinoma, Non-Small-Cell LungNCT00806819Boehringer Ingelheim718
已完成
1 期
BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase ICarcinoma, Non-Small-Cell LungNCT00876460Boehringer Ingelheim43
终止
2 期
BIIB023 Proof-of-Concept Study in Participants With Lupus NephritisLupus NephritisNCT01499355Biogen276